

In the Claims:

Amendments to the Claims:

This listing of Claims will replace all prior version, and listings, of Claims in the application:

1. (Currently amended) A method for perioperatively inhibiting ocular inflammation, inhibiting pain, effecting mydriasis, and/or decreasing intraocular pressure during an intraocular ophthalmologic procedure, comprising continuously irrigating intraocular tissues during an intraocular ophthalmologic procedure with a solution including at least first and second agents in a liquid irrigation carrier, the first and second agents being selected to act on a plurality of differing molecular targets, each agent being selected from the physiologic functional classes of anti-inflammatory agents, analgesic agents, mydriatic agents and agents for decreasing intraocular pressure ("IOP reducing agents"), the second agent providing at least one physiologic function different than a function or functions provided by the first agent, wherein at least one of the first and second agents is a mydriatic agent or an IOP reducing agent.
2. (Currently amended) The method of Claim 455, wherein the solution comprises an anti-inflammatory agent selected from the group consisting of steroids, non-steroidal anti-inflammatory drugs (NSAIDS), anti-histamines, mast cell inhibitors, and inhibitors of inducible nitric oxide synthase (iNOS).
3. (Original) The method of Claim 2, wherein: the steroid, if selected, is selected from the group consisting of dexamethasone, fluorometholone and prednisolone; the NSAID, if selected, is selected from the group consisting of flurbiprofen, suprofen, diclofenac, ketoprofen and ketorolac; the anti-histamine, if selected, is selected from the group consisting of levocabastine, emedastine, olopatadine, ketotifen, and azelastine; the mast cell inhibitor, if selected, is selected from the group consisting of cromolyn sodium, Iodoxamide, nedocromil, ketotifen and azelastine; and the inhibitor of iNOS, if selected, is selected from the group consisting of N^G-monomethyl-L-arginine, 1400 W, diphenyleneiodonium, S-methyl isothiourea, S-(aminoethyl) isothiourea, L-N⁶-(1-iminoethyl)lysine, 1,3-PBITU and 2-ethyl-2-thiopseudourea.

OMEROS CORPORATION
1420 Fifth Avenue
Suite 2600
Seattle, Washington 98101
206.623.4688

4. (Currently amended) The method of Claim 4, wherein the solution comprises an analgesic agent selected from the group consisting of local anesthetics and opioids.

5. (Original) The method of Claim 4, wherein: the local anesthetic, if selected, is selected from the group consisting of lidocaine, tetracaine, bupivacaine, and proparacaine; and the opioid, if selected, is selected from the group consisting of morphine, fentanyl and hydromorphone.

6. (Currently amended) The method of Claim 4, wherein the solution comprises a mydriatic agent selected from the group consisting of alpha-1 adrenergic receptor agonists and anticholinergic agents.

7. (Original) The method of Claim 6, wherein: the alpha-1 adrenergic receptor agonist, if selected, is selected from the group consisting of phenylephrine, epinephrine, and oxymetazoline; and the anticholinergic agent, if selected, is selected from the group consisting of tropicamide, cyclopentolate, atropine and homatropine.

8. (Currently amended) The method of Claim 4, wherein the solution comprises an IOP reducing agent selected from the group consisting of beta adrenergic receptor antagonists, carbonic anhydrase inhibitors, alpha-2 adrenergic receptor agonists, and prostaglandin agonists.

9. (Original) The method of Claim 8, wherein: the beta adrenergic receptor antagonist, if selected, is selected from the group consisting of timolol, metipranolol and levobunolol; the carbonic anhydrase inhibitor, if selected, is selected from the group consisting of brinzolamide and dorzolamide; the alpha-2 adrenergic receptor agonist, if selected, is selected from the group consisting of apraclonidine, brimonidine and oxymetazoline; and the prostaglandin agonist, if selected, is selected from the group consisting of latanoprost, travoprost and bimatoprost.

10. (Currently amended) The method of Claim 4, wherein each of the first and second agents in the solution is included at a concentration of no more than 100,000 nanomolar.

11. (Currently amended) The method of Claim 4, wherein each of the first and second agents in the solution is included at a concentration of no more than 10,000 nanomolar.

12. (Currently amended) The method of Claim 4, wherein the liquid irrigation carrier further comprises an adjuvant selected from electrolytes sufficient to provide a physiological

OMEROS CORPORATION
1420 Fifth Avenue
Suite 2600
Seattle, Washington 98101
206.623.4688

balanced salt solution, a cellular energy source, a buffering agent, a free-radical scavenger and mixtures thereof.

13. (Original) The method of Claim 12, wherein: the electrolytes, if selected, comprise from 50 to 500 millimolar sodium ions, from 0.1 to 50 millimolar potassium ions, from 0.1 to 5 millimolar calcium ions, from 0.1 to 5 millimolar magnesium ions, from 50 to 500 millimolar chloride ions, and from 0.1 to 10 millimolar phosphate; the buffer, if selected, comprises bicarbonate at a concentration of from 10 to 50 millimolar; the cellular energy source if selected, is selected from dextrose and glucose and is present at a concentration of from 1 to 25 millimolar; and the free-radical scavenger, if selected, comprises glutathione at a concentration of from 0.05 to 5 millimolar.

14. (Currently amended) The method of Claim ~~455~~, wherein the liquid irrigation carrier further comprises electrolytes sufficient to provide a physiological balanced salt solution, a cellular energy source, a buffering agent and a free-radical scavenger.

15. (Original) The method of Claim 14, wherein: the electrolytes comprise from 50 to 500 millimolar sodium ions, from 0.1 to 50 millimolar potassium ions, from 0.1 to 5 millimolar calcium ions, from 0.1 to 5 millimolar magnesium ions, from 50 to 500 millimolar chloride ions, and from 0.1 to 10 millimolar phosphate; the buffer comprises bicarbonate at a concentration of from 10 to 50 millimolar; the cellular energy source is selected from dextrose and glucose and is present at a concentration of from 1 to 25 millimolar; and the free-radical scavenger comprises glutathione at a concentration of from 0.05 to 5 millimolar.

16. (Currently amended) The method of Claim ~~455~~, wherein the pH of the irrigation solution is between 5.5 and 8.0.

17. (Canceled)

18. (Currently amended) The method of Claim ~~455~~, wherein the first and second agents comprise one or more anti-inflammatory agents in combination with one or more IOP reducing agents, and optionally one or more analgesic and/or mydriatic agents.

OMEROS CORPORATION
1420 Fifth Avenue
Suite 2600
Seattle, Washington 98101
206.623.4688

19. (Currently amended) The method of Claim ~~455~~, wherein the first and second agents comprise one or more anti-inflammatory agents in combination with one or more mydriatic agents, and optionally one or more analgesic agents and/or IOP reducing agents.

20. (Currently amended) The method of Claim ~~455~~, wherein the first and second agents comprise one or more analgesic agents in combination with one or more IOP reducing agents, and optionally one or more anti-inflammatory agents and/or mydriatic agents.

21. (Currently amended) The method of Claim ~~455~~, wherein the first and second agents comprise one or more analgesic agents in combination with one or more mydriatic agents, and optionally one or more anti-inflammatory agents and/or IOP reducing agents.

22. (Currently amended) The method of Claim ~~455~~, wherein the first and second agents comprise one or more mydriatic agents in combination with one or more IOP reducing agents, and optionally one or more anti-inflammatory and/or analgesic agents.

23. (Currently amended) The method of Claim ~~455~~, wherein the solution comprises an NSAID, timolol and phenylephrine.

24. (Currently amended) The method of Claim ~~455~~, wherein the solution comprises an NSAID, timolol and tropicamide.

25. (Currently amended) The method of Claim ~~455~~, wherein the solution comprises oxymetazoline and an NSAID.

26. (Currently amended) The method of Claim ~~455~~, wherein the solution comprises a steroid, an NSAID, timolol and phenylephrine.

27. (Currently amended) The method of Claim ~~455~~, wherein the solution comprises timolol, an NSAID, tropicamide and a local anesthetic.

28. (Currently amended) A method for perioperatively inhibiting ocular inflammation, inhibiting pain, effecting mydriasis, and/or decreasing intraocular pressure during an intraocular ophthalmologic procedure, comprising irrigating intraocular tissues during an intraocular ophthalmologic procedure with a solution including at least first and second agents in a liquid irrigation carrier, the first and second agents being selected to act on a plurality of differing

OMEROS CORPORATION
1420 Fifth Avenue
Suite 2600
Seattle, Washington 98101
206.623.4688

molecular targets, each agent being selected from the physiologic functional classes of anti-inflammatory agents, analgesic agents, mydriatic agents and agents for decreasing intraocular pressure ("IOP reducing agents"), the second agent providing at least one physiologic function different than a function or functions provided by the first agent, each agent being included at a concentration of no more than 100,000 nanomolar, wherein at least one of the first and second agents is a mydriatic agent or an IOP reducing agent.

29 - 54. (Canceled)

55. (Currently amended) A method for perioperatively inhibiting ocular inflammation, inhibiting pain, effecting mydriasis, and/or decreasing intraocular pressure during an intraocular ophthalmologic procedure, comprising irrigating intraocular tissues during an intraocular ophthalmologic procedure with a solution including at least first and second agents in a liquid irrigation carrier, the first and second agents being selected to act on a plurality of differing molecular targets, each agent being selected from the physiologic functional classes of anti-inflammatory agents, analgesic agents, mydriatic agents and agents for decreasing intraocular pressure ("IOP reducing agents"), the second agent providing at least one physiologic function different than a function or functions provided by the first agent, wherein at least one of the first and second agents is a mydriatic agent or an IOP reducing agent.

56. (Canceled)

57. (New) A method for perioperatively inhibiting ocular inflammation, inhibiting pain, effecting mydriasis, and/or decreasing intraocular pressure during an intraocular ophthalmologic procedure, comprising irrigating intraocular tissues during an intraocular ophthalmologic procedure with a solution including at least first and second agents in a liquid irrigation carrier, the first and second agents being selected to act on a plurality of differing molecular targets, each agent being selected from the physiologic functional classes of anti-inflammatory agents, analgesic agents, mydriatic agents and agents for decreasing intraocular pressure ("IOP reducing agents"), the second agent providing at least one physiologic function different than a function or functions provided by the first agent, wherein the first agent comprises a mydriatic agent and the second agent comprises an anti-inflammatory agent.

OMEROS CORPORATION
1420 Fifth Avenue
Suite 2600
Seattle, Washington 98101
206.623.4688

58. (New) The method of Claims 57, wherein the mydriatic agent comprises an alpha-1 adrenergic receptor agonist and the anti-inflammatory agent comprises an NSAID.

59. (New) The method of Claims 58, wherein the mydriatic agent comprises phenylephrine and the anti-inflammatory agent comprises ketorolac.

OMEROS CORPORATION
1420 Fifth Avenue
Suite 2600
Seattle, Washington 98101
206.623.4688